SPINAL MUSCULAR ATROPHY: MODERN CONCEPTS OF PATHOGENESIS, DIAGNOSIS, AND TREATMENT

Authors

  • Н.Н. Эргашева Ташкентский Педиатрический Медицинский Институт Author
  • М.К. Темирова Ташкентский Педиатрический Медицинский Институт Author
  • Х.Д. Нурматова Ташкентский Педиатрический Медицинский Институт Author

Keywords:

SMA, motor neuron, atrophy, mutation, gene, degeneration.

Abstract

Spinal muscular atrophy (SMA) is a significant medical and social problem and one of the most common causes of childhood mortality due to hereditary neuromuscular diseases. SMA is an inherited motor neuron disease characterized by progressive muscle weakness and atrophy. It is one of the most frequent autosomal recessive neuromuscular disorders, with an incidence of 1:6000 – 1:10000 newborns, while the carrier frequency of the mutant SMN1 gene is found in 1 in 40–50 individuals in the population (Verhaart et al., 2017). Until recently, the disease was considered incurable; however, the emergence of new therapeutic approaches has significantly improved patient prognosis.

References

Werdnig G. Zwei frühinfantile hereditäre Fälle von progressive Muskelatrophie unter dem Bilde der Dystrophie, aber auf neurotischer Grundlage // Arch Psychiatr Nervenkr. 1891. Vol. 22. Р. 437–480. doi: 10.1007/BF01776636

Coret, F., & Aveledo, J. I. (2020). Spinal muscular atrophy: Current therapeutic options and future perspectives. Frontiers in Neurology, 11, 560300. https://doi.org/10.3389/fneur.2020.560300

Darras, B. T., Masson, R., Mazur, C., Yang, Q., Gheuens, S., & Tizzano, E. F. (2021). Risdiplam-treated infants with Type 1 spinal muscular atrophy versus historical controls. New England Journal of Medicine, 385(5), 427-435. https://doi.org/10.1056/NEJMoa2102047

Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., … & De Vivo, D. C. (2017). Nusinersen versus sham control in infantile-onset spinal muscular atrophy. New England Journal of Medicine, 377(18), 1723-1732. https://doi.org/10.1056/NEJMoa1702752

Mendell, J. R., Al-Zaidy, S. A., Lehman, K. J., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., … & Kissel, J. T. (2017). Single-dose gene-replacement therapy for spinal muscular atrophy. New England Journal of Medicine, 377(18), 1713-1722. https://doi.org/10.1056/NEJMoa1706198

Verhaart, I. E. C., Robertson, A., Wilson, I. J., Cook, S. F., Lochmüller, H., & Kirschner, J. (2017). Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy – a literature review. Orphanet Journal of Rare Diseases, 12, 124. https://doi.org/10.1186/s13023-017-0671-8

Wirth, B. (2020). Spinal muscular atrophy: In the challenge lies a solution. Trends in Neurosciences, 43(4), 306-322. https://doi.org/10.1016/j.tins.2020.02.003

Published

2025-03-31

How to Cite

SPINAL MUSCULAR ATROPHY: MODERN CONCEPTS OF PATHOGENESIS, DIAGNOSIS, AND TREATMENT. (2025). Eurasian Journal of Medical and Natural Sciences, 5(3 Part 2), 65-69. https://in-academy.uz/index.php/EJMNS/article/view/10914